Single-shot Outbreak Vaccine Provides Full Protection Against Ebola According to Results of New Animal Studies

03-May-2005

Crucell N.V. reported new results from its Ebola vaccine studies. The studies, conducted together with the Vaccine Research Center (VRC) of the US National Institutes of Health (NIH) and the US Army Research Institute of infectious diseases (USAMRIID), confirm previously published results showing that a single shot of the vaccine protected monkeys completely against a lethal Ebola challenge. These new results utilized vectors developed with Crucell's adenoviral vector and PER.C6® cell line technology, and show protection at lower doses than previously reported.

The results of the studies were detailed by Dr Nancy Sullivan, head of the VRC's Biodefense Research Section, at a scientific meeting held at USAMRIID in Fort Detrick, Maryland.

"The timely execution of a series of complex vaccine studies with our Ebola vaccine proves the viability and agility of public-private partnerships such as that between Crucell and the VRC," said Crucell's Chief Scientific Officer, Dr Jaap Goudsmit. "The combination of the VRC's Ebola know-how, USAMRIID's ability to perform Ebola-challenge studies and Crucell's vaccine technology was the key to the current success. It augurs well for the field of biodefense, and for future responses to potential infectious disease outbreaks such as the current Marburg crisis."

Crucell recently secured an exclusive license to patents of the NIH for the development and commercialisation of recombinant vaccines against Ebola.

https://www.bionity.com/en/news/45684/single-shot-outbreak-vaccine-provides-full-protection-against-ebola-according-to-results-of-new-animal-studies.html